Contact Us
Drug Search Results
More Filters [+]

NBI-74788

Alternative Names: nbi-74788, nbi74788, nbi 74788
Latest Update: 2024-10-18
Latest Update Note: Clinical Trial Update

Product Description

Neurocrine is developing nbi-74788, an Oral CRFR Antagonist for Congenital Adrenal Hyperplasia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04045145)

Mechanisms of Action: CRFR Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Neurocrine
Company Location: SAN DIEGO CA 92130
Company CEO: Kevin C. Gorman
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NBI-74788

Countries in Clinic: Austria, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Serbia, Spain, Sweden, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Adrenal Hyperplasia, Congenital|Adrenocortical Hyperfunction|Adrenogenital Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NBI-74788-CAH2006

P3

Unknown Status

Adrenal Hyperplasia, Congenital

2027-10-31

NBI-74788-CAH3003

P3

Unknown Status

Adrenal Hyperplasia, Congenital

2027-08-31

2020-004381-19

P3

Active, not recruiting

Adrenal Hyperplasia, Congenital

2024-04-15

CAHtalyst

P3

Active, not recruiting

Adrenogenital Syndrome|Adrenal Hyperplasia, Congenital|Adrenocortical Hyperfunction

2023-07-19

Recent News Events

Date

Type

Title

03/15/2024

PubMed

 Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!

10/30/2023

PubMed

 Current and future perspectives on clinical management of classic 21-hydroxylase deficiency.

10/18/2023

PubMed

 Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.

05/12/2023

News Article

 Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

03/20/2021

News Article

 Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021

06/08/2020

News Article

 Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

05/21/2019

News Article

 AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions